| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Topotecan 4mg/4ml
|
| Product Type |
Product Size |
| Tablet |
20'S |
| Product Company |
| Mass Pharma |
Amlodipine 5mg
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Pfizer
|
Cisplatin 50mg
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Himmel Pharma |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Fresenius kabi |
Cytarabine 500mg/50ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Carboplatin 150mg/15ml |
| Content | Topotecan is an antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer.
| Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart
| Cisplatin is a platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas, and germ cell tumors. | Docetaxel is a taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer. | Cytarabine is a medication used in the management and treatment of leukemias and lymphomas. It belongs to the antimetabolic group of medications. This activity reviews the indications, action, and contraindications for cytarabine as a valuable agent in treating acute myeloid leukemia (and other leukemias. | Carboplatin is an alkylating agent used to treat advanced ovarian cancer.Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
|
Reviews
There are no reviews yet.